Premium
ATEZOLIZUMAB + OBINUTUZUMAB + VENETOCLAX IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA: PRIMARY ANALYSIS OF A PHASE 2 TRIAL FROM LYSA
Author(s) -
Cartron G.,
Bachy E.,
Guidez S.,
Gyan E.,
Gressin R.,
Morineau N.,
Sibon D.,
Casasnovas O.,
Le Gouill S.,
Tilly H.,
Ysebaert L.,
Schiano de Colella J. M.,
Feugier P.,
Virelizier E. Nicolas,
Haioun C.,
Damaj G.,
Tarte K.,
Laurent C.,
Houot R.,
Thieblemont C.,
Morschhauser F.,
Herbaux C.
Publication year - 2021
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.22_2880
Subject(s) - medicine , obinutuzumab , follicular lymphoma , venetoclax , oncology , alemtuzumab , rituximab , lymphoma , gastroenterology , leukemia , chronic lymphocytic leukemia , transplantation